Literature DB >> 6544125

Delivery of ricin and abrin A-chains to human carcinoma cells in culture following covalent linkage to monoclonal antibody LICR-LOND-Fib 75.

J A Forrester, D P McIntosh, A J Cumber, G D Parnell, W C Ross.   

Abstract

With the object of generating specific cytotoxic agents, we have prepared covalent conjugates of the A-chains of ricin and of abrin with monoclonal antibody LICR-LOND-Fib 75 and investigated their toxicity toward a human tumor cell line in culture. Both conjugates proved to be potent cytotoxins toward cells carrying the appropriate antigen. The agent containing abrin A-chain was toxic at a significantly lower concentration and exerted its maximum effect more rapidly than the one containing ricin A-chain. Inclusion of chloroquine in the incubation medium significantly enhanced the toxic action of both conjugates without loss of immunospecificity. Because of the widespread occurrence on human tumor cell lines of the antigen recognized by Fib 75, these conjugates, particularly the one containing abrin A-chain, may find application in freeing human bone marrow ex vivo of infiltrated tumor cells prior to reinfusion as an autograft.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6544125     DOI: 10.1089/cdd.1984.1.283

Source DB:  PubMed          Journal:  Cancer Drug Deliv        ISSN: 0732-9482


  9 in total

1.  Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer.

Authors:  E J Wawrzynczak; E J Derbyshire; R V Henry; G D Parnell; A Smith; R Waibel; R A Stahel
Journal:  Br J Cancer Suppl       Date:  1991-06

2.  Monoclonal antibodies recognising the cluster 2 antigen associated with human small cell lung cancer mediate the toxic effects of ricin A chain in an indirect assay of immunotoxin cytotoxicity.

Authors:  E J Derbyshire; E J Wawrzynczak
Journal:  Br J Cancer Suppl       Date:  1991-06

3.  Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.

Authors:  E J Wawrzynczak; G J Watson; A J Cumber; R V Henry; G D Parnell; E P Rieber; P E Thorpe
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy.

Authors:  M D Vincent; T J Powles; R C Coombes; T J McElwain
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Immunoconjugate generation between the ribosome inactivating protein restrictocin and an anti-human breast carcinoma MAB.

Authors:  R Orlandi; S Canevari; F P Conde; F Leoni; D Mezzanzanica; M Ripamonti; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  The effect of ricin B chain on the intracellular trafficking of an A chain immunotoxin.

Authors:  J Timar; D P McIntosh; R Henry; A J Cumber; G D Parnell; A J Davies
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

7.  Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.

Authors:  E J Wawrzynczak; E J Derbyshire; R V Henry; G D Parnell; A Smith; R Waibel; R A Stahel
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

Review 8.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

9.  Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer.

Authors:  E J Wawrzynczak; U Zangemeister-Wittke; R Waibel; R V Henry; G D Parnell; A J Cumber; M Jones; R A Stahel
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.